Skip to main content

Table 4 Multivariate Cox regression analysis including established prognostic parameters and the TFAP2D expression in all prostate cancers and in the subsets of ERG negative and ERG positive prostate cancers

From: Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

Tumor subsetScenarionp-value
preoperative PSA-LevelpT StagecT StageGleason grade prostatectomyGleason grade biopsypN stageR statusTFAP2D Expression
all cancers110,827<.0001*<.0001*<.0001*<.0001*<.0001*0.2379
210,846<.0001*<.0001*<.0001*<.0001*0.2712
310,692<.0001*<.0001*<.0001*0.0496*
49204<.0001*<.0001*<.0001*0.0007*
ERG-negative cancers14327<.0001*<.0001*<.0001*0.8751<.0001*0.4114
24334<.0001*<.0001*<.0001*0.0040*0.4285
34298<.0001*<.0001*<.0001*0.1722
44228<.0001*<.0001*<.0001*0.0007*
ERG- postive cancers13429<.0001*<.0001*<.0001*<.0001*0.0001*0.61
23437<.0001*<.0001*<.0001*<.0001*0.822
33383<.0001*<.0001*<.0001*0.8684
43327<.0001*<.0001*<.0001*0.2301
  1. Scenario 1 includes all postoperatively available parameters (pathological tumor (pT) stage, lymph node (pN), surgical margin (R) status, preoperative PSA value and Gleason grade obtained after the morphological evaluation of the entire resected prostate. Scenario 2 excluded the nodal status from analysis. Scenario 3 included preoperative PSA, clinical tumor (cT) stage and Gleason grade obtained on the prostatectomy specimen. In scenario 4, the preoperative Gleason grade obtained on the original biopsy was combined with preoperative PSA, and cT stage (* = significant)